CD47 and breast cancer: The MYC pathway, PD-L1 (CD274) and CD47 were elevated in TNBC, particularly in PTEN-low/miRNA-low TNBCs (group “a”), relative to HER2+ or ER+ breast cancer in most cohorts (Supplemental Fig. 9B–D).